ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 957,47
0,37%
DAX
17 932,17
-1,10%
Brent Oil
83,375
-2,93%
Bitcoin
57 950,56
-4,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Oncorus Inc (ONCR)

  7. Oncorus Inc (ONCR) Actualités

ONCR

Oncorus (ONCR)

Oncorus Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ONCR
DateHeureSourceTitreSymboleSociété
07/08/202312h52Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ONCROncorus Inc
03/08/202323h00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ONCROncorus Inc
03/08/202322h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ONCROncorus Inc
26/06/202322h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ONCROncorus Inc
23/06/202312h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ONCROncorus Inc
16/06/202315h21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ONCROncorus Inc
12/06/202312h45Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ONCROncorus Inc
01/06/202322h05GlobeNewswire Inc.Oncorus Announces Workforce Reduction PlanNASDAQ:ONCROncorus Inc
22/05/202322h05GlobeNewswire Inc.Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
16/05/202322h38Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ONCROncorus Inc
01/05/202313h36Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ONCROncorus Inc
24/03/202321h08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ONCROncorus Inc
24/03/202312h00GlobeNewswire Inc.Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
14/02/202314h05Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ONCROncorus Inc
04/01/202313h00GlobeNewswire Inc.Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug CandidatesNASDAQ:ONCROncorus Inc
28/12/202200h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ONCROncorus Inc
22/12/202212h02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ONCROncorus Inc
30/11/202213h00GlobeNewswire Inc.Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with CancerNASDAQ:ONCROncorus Inc
23/11/202214h00GlobeNewswire Inc.Oncorus to Participate in Upcoming Investor ConferencesNASDAQ:ONCROncorus Inc
18/11/202214h00GlobeNewswire Inc.Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual MeetingNASDAQ:ONCROncorus Inc
07/11/202212h15TipRanksOncorus (ONCR) Gets a Buy from H.C. WainwrightNASDAQ:ONCROncorus Inc
02/11/202221h32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ONCROncorus Inc
02/11/202212h00GlobeNewswire Inc.Oncorus Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
01/11/202221h07Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ONCROncorus Inc
07/10/202215h00GlobeNewswire Inc.Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of CancerNASDAQ:ONCROncorus Inc
26/09/202213h00GlobeNewswire Inc.Oncorus to Present at Chardan’s 6th Annual Genetic Medicines ConferenceNASDAQ:ONCROncorus Inc
06/09/202213h00GlobeNewswire Inc.Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:ONCROncorus Inc
15/08/202212h15TipRanksH.C. Wainwright Sticks to Its Buy Rating for Oncorus (ONCR)NASDAQ:ONCROncorus Inc
04/08/202213h00GlobeNewswire Inc.Oncorus Reports Second Quarter 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
23/06/202213h00GlobeNewswire Inc.Oncorus Appoints Douglas Fambrough to Board of DirectorsNASDAQ:ONCROncorus Inc
 Showing the most relevant articles for your search:NASDAQ:ONCR

Dernières Valeurs Consultées

FTSE
UKX
FTSE 100
NASDAQ
NVDA
NVIDIA
EU
RI
Pernod Ricard
EU
LR
Legrand
EU
EN
Bouygues
EU
PX4
SBF 120
NYSE
MRK
Merck
EU
ML
Michelin
NASDAQ
GOOGL
Alphabet
EU
SGO
Cie de SaintGobain
EU
BN
Danone
EU
RNO
Renault
EU
CAP
Capgemini
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés